|Rapid Review Complete
|For the treatment of osteosarcoma.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|Full Pharmacoeconomic Evaluation Recommended
A formal PEA is required to demonstrate value for money prior to reimbursement.
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.